• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Moringa Acquisition Corp

    8/26/24 9:49:09 AM ET
    $MACA
    Blank Checks
    Finance
    Get the next $MACA alert in real time by email
    15-12G 1 ea0212376-1512g_moringa.htm FORM 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

    SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

    OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Commission File Number: 001-40073

     

    MORINGA ACQUISITION CORP

    (Exact name of registrant as specified in its charter)

     

    250 Park Avenue, 7th Floor
    New York, NY, 10017

    (212) 572-6395

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Class A ordinary shares, par value $0.0001 per share

    Redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50

    Units, each consisting of one Class A ordinary share and one-half of a redeemable warrant

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

      Rule 12g-4(a)(1) ☒
      Rule 12g-4(a)(2) ☐
      Rule 12h-3(b)(1)(i) ☒
      Rule 12h-3(b)(1)(ii) ☐
      Rule 15d-6 ☐
      Rule 15d-22(b) ☐

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Moringa Acquisition Corp has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: August 26, 2024 Moringa Acquisition Corp
         
      By: /s/ Ilan Levin
      Name:  Ilan Levin
      Title: Director

     

     

     

     

     

    Get the next $MACA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MACA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MACA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Hudson Bay Capital Management Lp disposed of $4,253,473 worth of Class A Ordinary Shares (401,271 units at $10.60)

      4 - Moringa Acquisition Corp (0001835416) (Issuer)

      8/24/23 2:31:41 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 3: New insider Hudson Bay Capital Management Lp claimed ownership of 401,271 units of Class A Ordinary Shares

      3 - Moringa Acquisition Corp (0001835416) (Issuer)

      4/5/23 4:59:51 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/14/24 6:28:12 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/12/24 4:24:57 PM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Moringa Acquisition Corp (Amendment)

      SC 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      2/8/24 1:16:56 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Moringa Acquisition Corp

      SCHEDULE 13G/A - Moringa Acquisition Corp (0001835416) (Subject)

      8/27/24 11:00:41 AM ET
      $MACA
      Blank Checks
      Finance
    • SEC Form 15-12G filed by Moringa Acquisition Corp

      15-12G - Moringa Acquisition Corp (0001835416) (Filer)

      8/26/24 9:49:09 AM ET
      $MACA
      Blank Checks
      Finance
    • Moringa Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - Moringa Acquisition Corp (0001835416) (Filer)

      8/21/24 4:05:08 PM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

      Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

      9/9/24 7:32:00 AM ET
      $MACA
      $SLXN
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

      MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

      8/15/24 4:05:00 PM ET
      $MACA
      Blank Checks
      Finance
    • Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp

                                             Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

      2/22/24 8:27:00 AM ET
      $MACA
      Blank Checks
      Finance

    $MACA
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

      JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti

      3/21/22 4:05:00 PM ET
      $DRTS
      $MACA
      $VBLT
      Medical/Dental Instruments
      Health Care
      Blank Checks
      Finance